Clear Search

Showing 3 results for “Costenbader KH”.

November 2024

Efficacy and safety of sodium-glucose co-transporter 2 inhibitors for the primary prevention of cardiovascular, renal events and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: A population-based target trial emulation

Arthritis Rheumatol 2024. Epub ahead of print DOI: 10.1002/art.43037

Ma et al. assessed the efficacy and safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) compared with dipeptidyl peptidase 4 inhibitors (DPP4i) in preventing cardiovascular and renal events in patients with both SLE and type 2 diabetes (T2D). SGLT2i use significantly reduced risks for acute kidney injury, chronic kidney disease, end-stage renal disease, and heart failure, though it increased genital infection risk.

more…

May 2023
February 2022

Real-world Impact of Flaring on Patient-Reported Outcomes and Healthcare Resource Utilisation in Systemic Lupus Erythematosus

Clin Exp Rheumatol. 2021.Epub ahead of print

Data from the real world underscores the need for more effective strategies and treatments to alleviate or prevent flaring in systemic lupus erythematosus (SLE).

Despite data from Hong Kong and Canada showing an association of flaring with reduced health-related quality of life and increased healthcare resourse utilisation and costs, similar international data are limited.

more…